Antiviral Drugs - Lesotho

Lesotho

The projected revenue for the Antiviral Drugs market in Lesotho is expected to reach US$0.84m in 2024.
It is anticipated that the revenue will display an annual growth rate (CAGR 2024-2029) of 2.06%, leading to a market volume of US$0.93m by 2029.
When compared globally, United States is projected to generate the highest revenue with US$30,640.00m in 2024.
In Lesotho, the demand for antiviral drugs has significantly increased due to the high prevalence of HIV/AIDS in the country.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Antiviral Drugs market in Lesotho has been steadily growing in recent years, driven by several factors unique to the country.

Customer preferences: Lesotho has a high prevalence of HIV/AIDS, with one of the highest infection rates in the world. As a result, there is a high demand for antiviral drugs in the country. In addition, the country has a growing elderly population, which is also driving demand for antiviral drugs.

Trends in the market: The Antiviral Drugs market in Lesotho has been experiencing steady growth in recent years, with an increasing number of pharmaceutical companies entering the market. This has led to increased competition, which has in turn led to lower prices for consumers. In addition, there has been a shift towards more targeted antiviral drugs, which are more effective and have fewer side effects.

Local special circumstances: Lesotho is a small, landlocked country with a relatively small population. This has made it difficult for pharmaceutical companies to establish a strong presence in the country. However, the government has been working to attract more investment in the pharmaceutical sector, which has led to an increase in the number of companies operating in the country.

Underlying macroeconomic factors: Lesotho has a relatively stable economy, with a growing middle class and a high level of foreign investment. This has helped to drive demand for antiviral drugs, as consumers have more disposable income to spend on healthcare. In addition, the government has been investing heavily in healthcare infrastructure, which has helped to improve access to antiviral drugs for the population.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.